Canadian Institutes of Health Research (CIHR)

The Canadian Institutes of Health Research (CIHR) is Canada’s federal health research funding agency, disbursing over $1 billion annually across 13 virtual institutes—including the Institute of Neurosciences, Mental Health and Addiction, which has funded landmark psychedelic medicine trials such as ketamine for bipolar depression at Braxia Scientific and psilocybin-assisted therapy studies at multiple Canadian universities. As the primary source of government funding for psychedelic research in Canada, CIHR plays a pivotal role in building the evidence base for novel psychiatric treatments.